Tuesday, October 16, 2012

Teva Halts Phase 3 trial on biosimilar Rituximab (Mabthera)

Teva was developing Rituximab biosimilar in collaboration with Switzerland based biopharma contract manufacturing major Lonza. Other companies that are also in advanced stages of developing Rituximab biosimilar include Sandoz, Celtrion, Boehringer Ingelheim, Pfizer and Merck.

Mabthera / Rituxan (rituximab) is Roche’s blockbuster cancer and rheumatoid arthritis treatment and ranks among the top three biological drugs worldwide. It generated US$6.6 billion sales in 2011.  Rituxan’s patent protection will expire in Europe in 2013 and in 2018 in the US.